Additionally, treatment with HDC was shown to increase the number of tumor-infiltrating effector CD8+ T cells in murine lymphoma and to improve the antitumor efficacy of immune checkpoint inhibitors (anti-PD-1 and anti-PD-L1) [148], thus implying that HDC may facilitate also T cell-dependent elimination of tumor cells. The gene discussed is CD8A; the disease is neoplasm.